Xilis is a biotechnology company developing a precision oncology platform that guides treatment decisions for oncologists to improve cancer care outcomes for patients and enables drug discovery and development with pharmaceutical companies. Xilis' proprietary MicroOrganoSphere™ (MOS) technology consists of miniature patient tumors that capture the full microenvironment and heterogeneity and provides an automated and scalable solution.
Market
Precision Oncology
Location
Durham,
North Carolina,
USA
Coinvestors
Alexandria Venture Investments, Alix Ventures, Catalio Capital, Duke Angel Network, EQT Life Sciences, Felicis Ventures, FPV Ventures, GVMubadala Capital, Pear Ventures, Two Sigma Ventures